TITLE:
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

CONDITION:
Parkinson Disease

INTERVENTION:
sumanirole

SUMMARY:

      The primary purpose of this study is to determine whether sumanirole, at three different
      dose levels, is effective and safe in the treatment of the signs and symptoms of early
      Parkinson's disease
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 30 Years to N/A
Criteria:

        Inclusion Criteria:

        Idiopathic Parkinson's disease < 7 years duration

        Modified Hoehn and Yahr Scale Stages I through III

        Age greater than or equal to 30 years old

        Patients or their partners must use adequate contraceptive methods

        Patients who are willing and able to comply with scheduled visits, treatment plan,
        laboratory tests, and other study procedures and do not plan on traveling extensively
        during the study

        Exclusion Criteria:

        Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or
        degenerative diseases.

        Levodopa received for 1-year accumulated interval in the last two years.

        Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days
        prior to baseline.

        Unstable dose regimes of hypnotics, anxiolytics or antidepressants

        Dementia

        History of stereotaxic brain surgery, psychosis or active epilepsy within past year.

        Participation in clinical trial within the previous 30 days.

        Malignant melanoma or history of melanoma

        Significant medical or pshychiatric condition
      
